Biogen Inc. stock underperforms Friday when compared to competitors
Biogen Inc. closed 41.60% below its 52-week high of $246.44, which the company achieved on February 7th.
Biogen Inc. (NASDAQ:BIIB) Shares Sold by Fifth Third Bancorp
Fifth Third Bancorp reduced its stake in Biogen Inc. (NASDAQ:BIIB – Free Report) by 3.4% in the fourth quarter, ...
FierceBiotech9d
Biogen research team hit by layoffs as company shifts resources to external opportunities
Biogen has been in the news recently after longtime partner Sage Therapeutics filed a lawsuit against the company after ...
Sage rejects Biogen's $469 million takeover offer, says offer undervalues company
Sage Therapeutics said on Monday that its board has unanimously rejected Biogen’s $469 million offer, stating it ...
Sage rejects Biogen’s buyout offer, but says it's open to deals
Sage Therapeutics has rejected the unsolicited acquisition offer it received earlier this month from longtime partner Biogen ...
FiercePharma10d
Sage sues Biogen as analyst detects little interest in buyout at original offer price
Sage Therapeutics has brought a lawsuit against Biogen shortly after receiving an “unsolicited” offer from its neuroscience ...
Biogen (BIIB) Gets a Hold from Piper Sandler
In a report released today, David Amsellem from Piper Sandler maintained a Hold rating on Biogen (BIIB – Research Report), with a price target ...
Biogen CEO tells Governor Healey he’s concerned about ‘a lot more policy risk’ in D.C.
Chris Viehbacher spoke out about the uncertain policy environment for life sciences companies, though he didn't single ...
Biogen, Eisai: EC Asks CHMP to Take Another Look at Leqembi
Biogen and Eisai said they believe that EC's requests can be addressed with existing information, and that no new safety signals have been identified for Leqembi. The U.S. Food and Drug Administration ...